* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Presentation - University of Warwick
Therapeutic gene modulation wikipedia , lookup
Deoxyribozyme wikipedia , lookup
Nucleic acid analogue wikipedia , lookup
Epigenetics of human development wikipedia , lookup
Polyadenylation wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
RNA interference wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Nicotinic acid adenine dinucleotide phosphate wikipedia , lookup
Primary transcript wikipedia , lookup
Nucleic acid tertiary structure wikipedia , lookup
Epitranscriptome wikipedia , lookup
History of RNA biology wikipedia , lookup
RNA-binding protein wikipedia , lookup
RNA silencing wikipedia , lookup
Mir-92 microRNA precursor family wikipedia , lookup
Life or Cell Death: Deciphering c-Myc Regulated Gene Networks In Two Distinct Tissues Sam Robson MOAC DTC, Coventry House, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL [email protected] Mco A Talk Outline 1. 2. 3. 4. 5. 6. 7. Introduction Skin vs. Pancreas Methods Quality Control Results Linear Models Conclusions Project Aims • • • • Analyse differences in gene-expression between two models of c-Myc activation with distinctly opposing phenotypes Identify c-Myc targets that promote cell replication/survival and apoptotic cell death to help understand dual potential of c-Myc To improve understanding of the complex activity of c-Myc in diseases such as cancer To understand how c-Myc regulates vastly different paradoxical phenotypes in vivo 1: Introduction • Transcription factor- wide range of cellular functions • “Master regulator of genes” • Deregulated in majority of human cancers • Possible therapeutic target? • We know WHAT c-Myc does, but we want to know WHY it does it c-Myc Regulated Processes Angiogenesis External Signals Growth c-Myc Loss of Differentiation (eg. mitogens, survival factors) Apoptosis Proliferation 2: Skin vs. Pancreas • Controlled activation of c-Myc in target cells of adult mice in vivo • Targetted to pancreatic islet β-cells (insulin promoter) and skin suprabasal keratinocytes (involucrin promoter) • Opposing phenotypic outcomes TAM c-MycER Activation Inactive Skin Suprabasal layer Pancreas Pelengaris et al. (1999), Molecular Cell, Vol. 3(5), 565-577 Pelengaris et al. (2002), Cell, Vol. 109(3), 321-334 Active Suprabasal layer TAM c-MycER Activation • Skin Unchecked proliferation, no apoptosis - Replication • Pancreas Synchronous cell cycle entry and apoptosis – Death • Myc activation regulates two opposing phenotypes Pelengaris et al. (1999), Molecular Cell, Vol. 3(5), 565-577 Pelengaris et al. (2002), Cell, Vol. 109(3), 321-334 3: Methods 1: Treatment of Transgenics 2: Extraction of Tissue Controlled activation of c-Myc in two diverse tissues 6: Microarray Hybridisation 3: Laser Capture Microdissection Excision of target tissue QC 5: 2-Cycle IVT Preparation of cRNA for microarray hybridisation Hybridise fragmented, labelled cRNA to microarrays Isolation of homogenous tissue QC 4: RNA Extraction Isolate total RNA from target cells QC 7: Microarray Data Analysis Analysis of microarray data QC 8: Validation Studies 9: Functional Validation Validation studies to confirm results Linking results to the biology of the system Experimental Setup Myc OFF Myc ON Gene Expression Skin Tissue Time course n=3 Gene Expression Time course n=3 4hr 8hr 16hr 4hr 32hr 16hr 32hr Time course n=3 Gene Expression Pancreas Tissue Gene Expression Time course n=3 8hr 4hr 8hr 16hr 32hr 4hr 8hr 16hr 32hr Laser Capture Microdissection Laser LCM Eppendorf Tube Membrane Slide Tissue Glass Slide Support • β-cells make up only ~2% of pancreas • Interesting changes masked by changes in non-Myc encoding cells • LCM allows isolation of homogenous cell populations • Nikon SL Microcut LCM system Laser Capture Microdissection 1: Find Islet 2: Cut Islet 3: Lift Islet 4: Extracted Islet Laser Capture Microdissection 1: Find Islet 2: Cut Islet 3: Lift Islet 4: Extracted Islet Laser Capture Microdissection 1: Find Islet 2: Cut Islet 3: Lift Islet 4: Extracted Islet LCM Optimisation - Pancreas Control section 18s and 28s peaks nonexistent 18s and 28s peaks nonexistent 18s and 28s peaks nonexistent • Pancreas has large number of RNases • RNA Integrity decreases rapidly using standard LCM protocols (Arcturus Pixcell, PALM MicroBeam, etc.) • RNA fully degraded before reaching laser capture platform LCM Optimisation - Pancreas • All slides washed and baked before use • 100% ethanol used at all times • All surfaces cleaned thoroughly, gloves worn at all times, etc. • Don’t let tissue thaw (fix in ice-cold 100% ethanol) • Very quick staining (10 secs with 1% toluidine blue in 100% ethanol) • Air-dry sections in dessicator • Limit time on LCM platform (10 mins max) LCM Optimisation - Skin • • • • Difficult to cut – Strong cell-cell bonds Slow laser burns and damages cells Difficult to lift from surrounding tissue Area of captured tissue much smaller than for islets • Difficult to obtain sufficient RNA yield • LCM not essential for skin compared to pancreas – decided to stick to whole sections 4: Quality Control • Quality control at every stage: I. RNA extraction II. IVT III.Microarray hybridisation IV.Probe-level V. Post-normalisation Minimising Error • Technical Error – Same person performs all procedures – Meticulous planning – Standardise all protocols used – Randomisation of batches • Biological Error – Inbred transgenic mice used – All male – All same age – All culled at same time of day Quality Control • Quality control at every stage: I. RNA extraction II. IVT III.Microarray hybridisation IV.Probe-level V. Post-normalisation +/+ 4 (1) +/+ 4 (2) +/+ 4 (3) +/+ 8 (1) +/+ 8 (2) +/+ 8 (3) +/+ 16 (1) +/+ 16 (2) +/+ 16 (3) +/+ 32 (1) +/+ 32 (2) +/+ 32 (3) +/+ 72 (1) +/+ 72 (2) +/+ 72 (3) +/- 4 (1) +/- 4 (2) +/- 4 (3) +/- 8 (1) +/- 8 (2) +/- 8 (3) +/- 16 (1) +/- 16 (2) +/- 16 (3) +/- 32 (1) +/- 32 (2) +/- 32 (3) +/- 72 (1) +/- 72 (2) +/- 72 (3) -/+ 4 (1) -/+ 4 (2) -/+ 4 (3) -/+ 8 (1) -/+ 8 (2) -/+ 8 (3) -/+ 16 (1) -/+ 16 (2) -/+ 16 (3) -/+ 32 (1) -/+ 32 (2) -/+ 32 (3) -/+ 72 (1) -/+ 72 (2) -/+ 72 (3) -/- 4 (1) -/- 4 (2) -/- 4 (3) -/- 8 (1) -/- 8 (2) -/- 8 (3) -/- 16 (1) -/- 16 (2) -/- 16 (3) -/- 32 (1) -/- 32 (2) -/- 32 (3) -/- 72 (1) -/- 72 (2) -/- 72 (3) 4h 1 T 4h 2 T 4h 3 T 4h 1 U 4h 2 U 4h 3 U 8h 1 T 8h 2 T 8h 3 T 8h 1 U 8h 2 U 8h 3 U 16h 1 T 16h 2 T 16h 3 T 16h 1 U 16h 2 U 16h 3 U 32h 1 T 32h 2 T 32h 3 T 32h 1 U 32h 2 U 32h 3 U RIN RNA Integrity 10.0 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 RNA quality lower than threshold (RIN < 5) Quality Control • Quality control at every stage: I. RNA extraction II. IVT III.Microarray hybridisation IV.Probe-level V. Post-normalisation nd 2 Round cRNA Yield 2nd round cRNA yield ug 80 70 60 50 Standard Protocol 40 Double Volume Protocol 30 20 10 0 P60 P58 S9 S6 P41 S1 S10 S2 P42 S15 P44 P12 P28 S17 S16 P52 P25 P2 P27 P11 S11 P16 P6 Sample name • Standard protocol results in low cRNA yield – Possible contaminant? • Using double volume vastly improves yield – Contaminant diluted? +/+ 4 (1) +/+ 4 (2) +/+ 4 (3) +/+ 8 (1) +/+ 8 (2) +/+ 8 (3) +/+ 16 (1) +/+ 16 (2) +/+ 16 (3) +/+ 32 (1) +/+ 32 (2) +/+ 32 (3) +/+ 72 (1) +/+ 72 (2) +/+ 72 (3) +/- 4 (1) +/- 4 (2) +/- 4 (3) +/- 8 (1) +/- 8 (2) +/- 8 (3) +/- 16 (1) +/- 16 (2) +/- 16 (3) +/- 32 (1) +/- 32 (2) +/- 32 (3) +/- 72 (1) +/- 72 (2) +/- 72 (3) -/+ 4 (1) -/+ 4 (2) -/+ 4 (3) -/+ 8 (1) -/+ 8 (2) -/+ 8 (3) -/+ 16 (1) -/+ 16 (2) -/+ 16 (3) -/+ 32 (1) -/+ 32 (2) -/+ 32 (3) -/+ 72 (1) -/+ 72 (2) -/+ 72 (3) -/- 4 (1) -/- 4 (2) -/- 4 (3) -/- 8 (1) -/- 8 (2) -/- 8 (3) -/- 16 (1) -/- 16 (2) -/- 16 (3) -/- 32 (1) -/- 32 (2) -/- 32 (3) -/- 72 (1) -/- 72 (2) -/- 72 (3) 4h 1 T 4h 2 T 4h 3 T 4h 1 U 4h 2 U 4h 3 U 8h 1 T 8h 2 T 8h 3 T 8h 1 U 8h 2 U 8h 3 U 16h 1 T 16h 2 T 16h 3 T 16h 1 U 16h 2 U 16h 3 U 32h 1 T 32h 2 T 32h 3 T 32h 1 U 32h 2 U 32h 3 U 2nd round cRNA yield ug nd 2 Round cRNA Yield 100 90 80 70 60 50 40 30 20 10 0 Yield lower than recommended cutoff of 10 µg Effect of RNA Quality on Yield 2nd round cRNA yield ug 100 90 80 70 60 50 40 30 20 10 0 3 4 5 6 7 8 9 RIN • General trend between RNA quality and 2nd round cRNA yield – Weakly correlated • Low RIN does not necessarily mean poor yield • High RIN samples can still give low yield • RIN cannot accurately predict yield 10 Effect of RNA Quality on Yield • Skin samples have higher RNA quality and yield than pancreas samples • Many differences between skin and pancreas – Greater ribonuclease activity in pancreas – More intense processing for pancreas tissue RNA compared to skin Effect of RNA Extraction Batch Effect of 2-cycle IVT Batch Quality Control • Quality control at every stage: I. RNA extraction II. IVT III.Microarray hybridisation IV.Probe-level V. Post-normalisation Percent Present Low 2nd round cRNA yield (< 10 µg) Percent Present vs RNA Quality Percent Present vs RNA Yield +/+ 4 (1) +/+ 4 (2) +/+ 4 (3) +/+ 8 (1) +/+ 8 (2) +/+ 8 (3) +/+ 16 (1) +/+ 16 (2) +/+ 16 (3) +/+ 32 (1) +/+ 32 (2) +/+ 32 (3) +/+ 72 (1) +/+ 72 (2) +/+ 72 (3) +/- 4 (1) +/- 4 (2) +/- 4 (3) +/- 8 (1) +/- 8 (2) +/- 8 (3) +/- 16 (1) +/- 16 (2) +/- 16 (3) +/- 32 (1) +/- 32 (2) +/- 32 (3) +/- 72 (1) +/- 72 (2) +/- 72 (3) -/+ 4 (1) -/+ 4 (2) -/+ 4 (3) -/+ 8 (1) -/+ 8 (2) -/+ 8 (3) -/+ 16 (1) -/+ 16 (2) -/+ 16 (3) -/+ 32 (1) -/+ 32 (2) -/+ 32 (3) -/+ 72 (1) -/+ 72 (2) -/+ 72 (3) -/- 4 (1) -/- 4 (2) -/- 4 (3) -/- 8 (1) -/- 8 (2) -/- 8 (3) -/- 16 (1) -/- 16 (2) -/- 16 (3) -/- 32 (1) -/- 32 (2) -/- 32 (3) -/- 72 (1) -/- 72 (2) -/- 72 (3) 4h 1 T 4h 2 T 4h 3 T 4h 1 U 4h 2 U 4h 3 U 8h 1 T 8h 2 T 8h 3 T 8h 1 U 8h 2 U 8h 3 U 16h 1 T 16h 2 T 16h 3 T 16h 1 U 16h 2 U 16h 3 U 32h 1 T 32h 2 T 32h 3 T 32h 1 U 32h 2 U 32h 3 U Scale Factor Scale Factor 50 45 40 35 30 25 20 15 10 5 0 Low 2nd round cRNA yield (< 10 µg) Quality Control • Quality control at every stage: I. RNA extraction II. IVT III.Microarray hybridisation IV.Probe-level V. Post-normalisation Probe Level Models Example 1 Example 2 Example 3 .CEL File PLM Residuals Image • Pseudo-images of PLM summary - accounts for strong probe effects • Can see artefacts that may be otherwise hidden • Package affyPLM in Bioconductor in R Data Distribution – Pre-Normalised Pancreas Myc OFF Myc ON Skin Quality Control • Quality control at every stage: I. RNA extraction II. IVT III.Microarray hybridisation IV.Probe-level V. Post-normalisation Skin vs Pancreas Skin Pancreas • Clustering – Group similar samples together • Branching tree like structure – samples on the same branch most similar • Data cluster nicely on tissue (some outliers) • Given the protocol, the data looks great! Outliers Data Distribution – Post-Normalised Pancreas Myc OFF Myc ON Skin Removal of Outliers Outliers to be removed • Outliers tended to be poor across all QC tests • Good pancreas samples as outliers? • Remove or keep? Effect of RNA Quality on Outliers Sample QC Penalty 25 20 15 Pancreas 10 Skin 5 0 0 1 2 3 4 5 6 7 8 9 10 RIN • Outliers have wide range of RINs • Only one of four RIN < 5 samples classed as an outlier • Low RIN samples can produce good reproducible data Effect of RNA Yield on Outliers Sample QC Penalty 25 20 15 Pancreas 10 Skin 5 0 0 10 20 30 40 50 60 70 80 90 100 2nd Round cRNA Yield ug • Outliers have wide range of 2nd round cRNA yields • Only 4 of the outliers had low cRNA yields • Good quality data with less than 4 µg cRNA! 5: Results • Early time point analysis – looking for direct effects of c-Myc activation • Untreated versus Treated • Combined 4 and 8 hour time points • Analysis in Genespring GX • Two-way ANOVA on tissue type and treatment, p = 0.05 5: Results Gene Pancreas Skin Comments Insulin ↓ 4-fold nc Involucrin nc ↓ 2-fold Tissue-specific differentiation markers down Cyclin D2 nc ↑ 2-fold CDK4 nc ↑ 4-fold Cyclin E ↑ 4-fold nc p27KIP1 ↓ 2-fold ↓ 4-fold p19ARF ↑ 2-fold nc ODC ↑ 2-fold nc Fas receptor ↑ 6-fold nc Cell cycle progressors up & repressors down (some anomalies) Apoptotic markers up in pancreas 6: Linear Models • Close collaboration with Agilent Technologies for linear modelling of microarray data • Part of multidisciplinary PhD - MOAC • Bioconductor package in R, GUI in Tcl/Tk • Implementation in GeneSpring GX (Agilent) • Simple to use for non-statisticians • Work in Progress - currently testing the program on a number of diverse data sets Linear Models • Can be used in the following ways: 1.To ensure superfluous parameters have minimal effect on gene expression (eg batching effects) 2.To find interesting parameters 3.To find genes that change based on interesting parameters whilst taking other parameters and interactions into account (eg clinical data) Linear Models vs ANOVA Parameter 1 Interaction Parameter 2 LM ANOVA • LM with 2 factors equivalent to 2-way ANOVA • Comparable results to ANOVA • Found a few genes (163) more than ANOVA for parameter 2 – borderline p-values 7: Conclusions - What have I learnt? • Talk to people (Affymetrix, UKAffy, GeneSpring Users Group, R/Bioconductor community, conferences, colleagues, etc.) • Randomise everything • Keep things really, really clean (be paranoid!) • Plan everything with military precision • Minimum of four replicates if possible • You may still be able to get good results from poor quality RNA • Using double volume of reagents in 1st cycle of IVT reaction can increase overall cRNA yield Further Work • Analysis of microarray data • Use of LM tool and comparison of results with standard methods (ANOVA) • Validation of results – Immunohistochemistry, quantitative real time PCR, western blots, etc. • Functional validation – siRNA, ChIP-onchip, etc. • Thesis… Acknowledgements Project Supervisors: Michael Khan David Epstein Stella Pelengaris Special Thanks: Sheena Lee Paul Heath Geoff Scopes Giorgia Riboldi-Tunnicliffe Collaborators: Helen Brown Lesley Ward Sue Davis Heather Turner Ewan Hunter Sponsors: EPSRC, BBSRC, AICR, Eli Lilly and Amylin Pharmaceuticals Inc. Mco A Acknowledgements Outline of Talk 1. 2. 3. Introduction Skin vs. pancreas Methods i. ii. iii. iv. v. 4. 5. Overview and technical considerations Laser Capture Microscopy mRNA Isolation Microarray Hybridisation Microarray Analysis Results General linear models RNA Integrity Poor quality: Okay quality: Majority of peaks at lower levels 18S and 28S peaks more prominent, but many peaks at lower levels Good quality: Excellent quality: Fewer peaks at lower levels 18S and 28S peaks clear with almost no peaks at lower levels Cell-Cycle Progression Ub MYC MAX CCND2 CDK4 Cyclin D2 CDK4 CACGTG Proteosome E-Box sequence in promoter sequence of target gene CAK p27KIP1 Cyclin E CDK2 Active Inactive P MIZ-1 MYC MAX Sp1/Sp3 CUL1 CKS MYC p15Ink4b (CDKN2B) p21Waf1 (CDKN1A) Cell-Cycle Entry Apoptosis – Cell Death FAS Ligand FAS “Death Receptor” Death Induced Signalling Complex (DISC) FADD BID BCL-2 Apoptosome Procaspase 8 Caspase Cascade Effector ARF caspases FLIP BAX/ BAK tBID APAF-1 MOMP c-Myc Procaspase 9 Cytochrome c Smac DIABLO Mitochondrion ATP IAPs BIM IAPs PUMA Apoptosis p53 AIF NOXA Endo G Cellular targets Omi/ Htra2 Effector caspases Scatterplots Example 1 R2 R1 R3 R3 Example 2 R2 R1 R1 R3 R2 R1 R2 R3 Skin vs Pancreas Skin Pancreas • Clustering – Group similar samples together • Branching tree like structure – samples on the same branch most similar • Data cluster nicely on tissue (some outliers) • Given the protocol, the data looks great! Tissue-Specific Differentiation Markers Insulin ~4-fold down in pancreas Involucrin ~2-fold down in skin Cell-Cycle Progression Cyclin D2 ~2-fold up E Cyclin in skin ~4-fold up in pancreas • Ccnd2 and CDK4 upregulated in skin – Indicates G1/S cell cycle progression • No change in pancreas – Odd • CDK inhibitor p27 downregulated in both • Cyclin E upregulated in pancreas and not skin – Again, very odd CDK4 ~4-fold up in skin p27KIP1 ~2-fold down in pancreas ~4-fold down in skin Apoptosis p19ARF ~2-fold up in pancreas • Increase in p19 – Oncogenic stress (p53 dependent pathway) • No change in p53 at transcriptional level – Changes may occur at protein level • Massive increase in Fas receptor expression – Extrinsic pathway • Myc seems to drive apotosis through extrinsic and intrinsic pathways Fas Receptor ~6-fold up in pancreas p53 No change Linear Models • Unsupervised linear regressive technique. • Model gene-expression data as a linear combination of parameter variables: y b1 x1 b2 x2 ... b p x p y = (y1,…,yn)T is the response variable (gene-expression) for each sample xi = (x1,…,xn)T are the explanatory variables (1 ≤ i ≤ p) for each sample bi is the model coefficient for explanatory variable xi n is the number of samples, p is the number of parameters ε is some error term c-Myc Regulated Processes Angiogenesis External Signals Growth Loss of Differentiation c-Myc (eg. mitogens, survival factors) Proliferation Apoptosis Effect of RNA Quality on Outliers Sample QC Penalty 25 20 15 Pancreas 10 Skin 5 0 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 RIN • Outliers have wide range of RINs • Only one low RIN sample (RIN < 5) classed as an outlier • Low RIN samples can produce reproducible data Effect of RNA Yield on Outliers Sample QC Penalty 25 20 15 Pancreas 10 Skin 5 0 0 10 20 30 40 50 60 70 80 90 100 2nd Round cRNA Yield ug • Outliers have wide range of 2nd round cRNA yields • Only 4 of the outliers had low 2nd round cRNA • Good quality data with less than 4 µg 2nd round cRNA! Laser Capture Microdissection • Heterogeneity of tissue may cause problems • β-cells make up only ~2% of pancreas • Interesting changes masked by changes in non-Myc encoding cells • LCM allows isolation of homogenous cell populations Laser Capture Microdissection Laser LCM Eppendorf Tube Membrane Slide Tissue Glass Slide Support • Heterogeneity of tissue may cause problems • β-cells make up only ~2% of pancreas • Interesting changes masked by changes in non-Myc encoding cells • LCM allows isolation of homogenous cell populations